GRACE Score among Six Risk Scoring Systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) Demonstrated the Best Predictive Value for Prediction of Long-Term Mortality in Patients with ST-Elevation Myocardial Infarction
Jazyk angličtina Země Spojené státy americké Médium electronic-ecollection
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
25893501
PubMed Central
PMC4404322
DOI
10.1371/journal.pone.0123215
PII: PONE-D-14-54070
Knihovny.cz E-zdroje
- MeSH
- biologické modely MeSH
- časové faktory MeSH
- hospitalizace MeSH
- infarkt myokardu diagnostické zobrazování mortalita MeSH
- lidé středního věku MeSH
- lidé MeSH
- multivariační analýza MeSH
- následné studie MeSH
- plocha pod křivkou MeSH
- prediktivní hodnota testů MeSH
- propuštění pacienta MeSH
- rizikové faktory MeSH
- senioři MeSH
- srdeční selhání diagnóza MeSH
- ultrasonografie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
AIM: To compare the prognostic accuracy of six scoring models for up to three-year mortality and rates of hospitalisation due to acute decompensated heart failure (ADHF) in STEMI patients. METHODS AND RESULTS: A total of 593 patients treated with primary PCI were evaluated. Prospective follow-up of patients was ≥3 years. Thirty-day, one-year, two-year, and three-year mortality rates were 4.0%, 7.3%, 8.9%, and 10.6%, respectively. Six risk scores--the TIMI score and derived dynamic TIMI, CADILLAC, PAMI, Zwolle, and GRACE--showed a high predictive accuracy for six- and 12-month mortality with area under the receiver operating characteristic curve (AUC) values of 0.73-0.85. The best predictive values for long-term mortality were obtained by GRACE. The next best-performing scores were CADILLAC, Zwolle, and Dynamic TIMI. All risk scores had a lower prediction accuracy for repeat hospitalisation due to ADHF, except Zwolle with the discriminatory capacity for hospitalisation up to two years (AUC, 0.80-0.83). CONCLUSIONS: All tested models showed a high predictive value for the estimation of one-year mortality, but GRACE appears to be the most suitable for the prediction for a longer follow-up period. The tested models exhibited an ability to predict the risk of ADHF, especially the Zwolle model.
Zobrazit více v PubMed
Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291: 2727–2733. 10.1001/jama.291.22.2727 PubMed DOI
Addala S, Grines CL, Dixon SR, Stone GW, Boura JA, Ochoa AB, et al. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). The American Journal of Cardiology. 2004;93: 629–632. 10.1016/j.amjcard.2003.11.036 PubMed DOI
Amin ST, Morrow DA, Braunwald E, Sloan S, Contant C, Murphy S, et al. Dynamic TIMI Risk Score for STEMI. J Am Heart Assoc. 2013;2: e003269 10.1161/JAHA.112.003269 PubMed DOI PMC
De Luca G, Suryapranata H, van ‘t Hof AWJ, de Boer M-J, Hoorntje JCA, Dambrink J-HE, et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation. 2004;109: 2737–2743. 10.1161/01.CIR.0000131765.73959.87 PubMed DOI
Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial InfarctionThe CADILLAC Risk Score. J Am Coll Cardiol. 2005;45: 1397–1405. 10.1016/j.jacc.2005.01.041 PubMed DOI
Fox KAA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333: 1091 10.1136/bmj.38985.646481.55 PubMed DOI PMC
Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J. 2010;31: 943–957. 10.1093/eurheartj/ehp492 PubMed DOI PMC
Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, Lemos JA de, et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy. Circulation. 2000;102: 2031–2037. 10.1161/01.CIR.102.17.2031 PubMed DOI
Kozieradzka A, Kamiński KA, Maciorkowska D, Olszewska M, Dobrzycki S, Nowak K, et al. GRACE, TIMI, Zwolle and CADILLAC risk scores—Do they predict 5-year outcomes after ST-elevation myocardial infarction treated invasively? International Journal of Cardiology. 2011;148: 70–75. 10.1016/j.ijcard.2009.10.026 PubMed DOI
Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001;286: 1356–1359. PubMed
Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163: 2345–2353. 10.1001/archinte.163.19.2345 PubMed DOI
Steg GP, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33: 2569–2619. 10.1093/eurheartj/ehs215 PubMed DOI
Lev EI, Kornowski R, Vaknin-Assa H, Porter A, Teplitsky I, Ben-Dor I, et al. Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2008;102: 6–11. 10.1016/j.amjcard.2008.02.088 PubMed DOI
De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, et al. Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease. New England Journal of Medicine. 2012;367: 991–1001. 10.1056/NEJMoa1205361 PubMed DOI
Garg S, Sarno G, Serruys PW, Rodriguez AE, Bolognese L, Anselmi M, et al. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials. JACC Cardiovasc Interv. 2011;4: 66–75. 10.1016/j.jcin.2010.09.017 PubMed DOI
Stebbins A, Mehta RH, Armstrong PW, Lee KL, Hamm C, Van de Werf F, et al. A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention Results From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. Circ Cardiovasc Interv. 2010;3: 414–422. 10.1161/CIRCINTERVENTIONS.109.925180 PubMed DOI